Research Topics
Genomes and Genes | Beth Y KarlanSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerBeth Y Karlan
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 30:362-71. 2012....
Evolution through intelligent designBeth Y Karlan
Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA 90048-1865, USA
Gynecol Oncol 102:1-4. 2006- BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?Ilana Cass
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, Cedars Sinai Medical Centers, CA 90048, USA
Obstet Gynecol 106:1327-34. 2005..To compare clinical and histologic features between fallopian tube cancers in women with germline BRCA mutations and sporadic cases... - Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomasChristine S Walsh
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
Clin Cancer Res 14:7645-51. 2008..The importance of the BRCA gene products in maintaining genomic stability led us to hypothesize that BRCA-associated and sporadic ovarian cancers would have distinctive genetic profiles despite similarities in histologic appearance... - Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancerIdo Wolf
Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
Breast Cancer Res Treat 105:139-55. 2007..Thus, unmasking of epigenetic silencing in breast cancer enabled us to discover a large number of candidate tumor suppressor genes. Further analysis suggested a role of one of these genes, PTCH, in breast cancer tumorigenesis... - ERCC5 is a novel biomarker of ovarian cancer prognosisChristine S Walsh
Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
J Clin Oncol 26:2952-8. 2008..Gene expression analyses were performed through microarray experiments. Candidate genes were tested for independent effects on survival using Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test... - Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancersAndrew J Li
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
Gynecol Oncol 116:105-8. 2010..We hypothesized that AR CAG allele length is a modifier of clinical outcome in BRCA1/2 mutation positive women with ovarian cancer... - Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomasAndrew J Li
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Gynecol Oncol 109:220-5. 2008..We hypothesize short AR allelotypes promote aggressive ovarian cancer phenotype through modulation of epidermal growth factor receptor (EGFR) signaling... - Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasisMin Zhu
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA
Mol Cancer Ther 10:1500-8. 2011..The data suggest that blocking periostin expression may be a novel approach for treating the subset of invasive ovarian tumors that overexpress periostin protein... - Hereditary ovarian cancer--assessing risk and prevention strategiesJames C Pavelka
Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
Obstet Gynecol Clin North Am 34:651-65, vii-viii. 2007..In all mutation carriers who have completed or do not desire childbearing, prophylactic bilateral salpingo-oophorectomy must be strongly considered... - Periostin promotes ovarian cancer angiogenesis and metastasisMin Zhu
Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
Gynecol Oncol 119:337-44. 2010..In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis... - Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biologyAndrew J Li
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
Gynecol Oncol 107:420-3. 2007..We have hypothesized that the combination of these factors further manifests an aggressive ovarian cancer phenotype... - Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoproteinDaniel R Scoles
Women s Cancer Research Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, USA
Gynecol Oncol 116:109-16. 2010..Here we investigate the direct effects of low density lipoprotein (LDL) and oxidized LDL (oxLDL) on proliferation and the inhibitory effects of fluvastatin and a liver X receptor (LXR) agonist... - Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancerAmer K Karam
Division of Gynecologic Oncology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 9095, USA
Gynecol Oncol 114:246-52. 2009..We sought to examine the impact of EDR assay-guided therapy on the outcome of patients with EOC in the primary and recurrent settings... - Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrestIdo Wolf
Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
Int J Oncol 30:1529-37. 2007..Our data suggest that HNK is a systemically available, non-toxic inhibitor of breast cancer growth and should be examined for clinical applications... - Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cellsBarbie Taylor-Harding
Women s Cancer Research Institute and Division of Gynecologic Oncology, Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
Gynecol Oncol 119:549-56. 2010..We hypothesized that statins have a cytotoxic effect and that the combination of fluvastatin and cisplatin inhibits cellular proliferation in epithelial ovarian cancer cells... - Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasBarbara Norquist
University of Washington Medical Center, Department of Obstetrics and Gynecology, Box 356460, Seattle, WA, USA
J Clin Oncol 29:3008-15. 2011..We assessed primary and recurrent BRCA1/2-mutated ovarian carcinomas to define the frequency of secondary mutations and correlate these changes with clinical outcomes... - FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancerIdo Wolf
Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
Int J Cancer 120:1013-22. 2007..Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer... - Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screeningChristine S Walsh
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Gynecol Oncol 116:516-21. 2010..e. synchronous endometrial and ovarian cancer). Our study aims to estimate the prevalence of LS in these two populations... - Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?Ilana Cass
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Gynecol Oncol 117:27-31. 2010..Risk-reducing bilateral salpingo-oophorectomy (RRSO) is an effective option for women with BRCA mutations however there is limited information as to how much tubal epithelium remains after RRSO... - Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinomaAndrew J Li
Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Clin Cancer Res 9:3667-73. 2003..02). CONCLUSIONS: These data support epidemiological evidence linking heightened androgenicity to the pathogenesis and tumor biology of epithelial ovarian cancer... - Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancerNicole D Fleming
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, California 90048, USA
Cancer 118:689-97. 2012..The objective of this study was to determine whether single-nucleotide polymorphisms (SNPs) in NER pathway genes could be markers of platinum response in ovarian cancer... - Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKTDaniel R Scoles
Women s Cancer Research Institute at Samuel Oschin Comprehensive Cancer Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Gynecol Oncol 104:120-8. 2007..We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882... - Effect of obesity on survival in epithelial ovarian cancerJames C Pavelka
Cedars-Sinai Medical Center, Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA
Cancer 107:1520-4. 2006..These findings suggest an effect of excess body weight on tumor biology, and studies are under way to elucidate the molecular and hormonal mechanisms underlying these clinical observations... - The prognostic significance of thrombocytosis in uterine papillary serous carcinomasDimitry L Lerner
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
Gynecol Oncol 104:91-4. 2007..In light of the similarities between uterine papillary serous carcinomas (UPSC) and EOC, we sought to determine the incidence of thrombocytosis in UPSC and examine associations with clinico-pathologic features and survival... - Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcomeAmer K Karam
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
Gynecol Oncol 104:377-80. 2007..We sought to evaluate the impact of TCS on survival and to determine predictors of optimal tertiary resection... - A human ovarian carcinoma murine xenograft model useful for preclinical trialsJohn C Elkas
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Gynecol Oncol 87:200-6. 2002..04). CONCLUSIONS: This murine xenograft model of human ovarian carcinoma appears to be reliable and reproducible and has utility for the study of novel therapeutics... - Effect of cigarette smoking on epithelial ovarian cancer survivalYevgeniya J M Ioffe
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Reprod Med 55:346-50. 2010..To determine associations between smoking and survival in patients with ovarian cancer... - Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell culturesAndrew J Li
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Obstet Gynecol 189:22-7. 2003..Epidemiologic data suggest that the malignant transformation of ovarian epithelium may be linked to altered steroid hormone homeostasis... - CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancerNicole D Fleming
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
Gynecol Oncol 121:249-52. 2011..We hypothesized that a shorter time interval between CA125 elevation and SCS correlates with a higher likelihood of optimal resection among eligible patients... - AIB1 polymorphisms predict aggressive ovarian cancer phenotypeAndrew J Li
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048, USA
Cancer Epidemiol Biomarkers Prev 14:2919-22. 2005..We hypothesized that genotypic variations in the androgen-signaling pathway promote aggressive epithelial ovarian cancer biology, and sought to examine the effect of AIB1 genotype on clinical outcome... - Improved survival in women with BRCA-associated ovarian carcinomaIlana Cass
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center and University of California Los Angeles School of Medicine, Los Angeles, California 90048, USAA
Cancer 97:2187-95. 2003..The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma... - 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancerIdo Wolf
Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
Cancer Res 66:7818-23. 2006..Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway... - Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceElizabeth M Swisher
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
Cancer Res 68:2581-6. 2008..Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors... - Quality of care in advanced ovarian cancer: the importance of provider specialtyCheryl Mercado
Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6904, USA
Gynecol Oncol 117:18-22. 2010..We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer... - Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?Nicole D Fleming
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
Gynecol Oncol 120:189-92. 2011..The purpose of this study is to assess if age is an independent poor prognostic factor in endometrioid histologies... - The prognostic significance of thrombocytosis in epithelial ovarian carcinomaAndrew J Li
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Gynecol Oncol 92:211-4. 2004..Thrombocytosis (platelet counts >400 x 10(9)/l) has been identified as a poor prognostic factor in many cancers. Platelet-secreted factors may contribute to metastasis, invasion, and primary tumor growth... - The role of genetic testing for cancer susceptibility in gynecologic practiceBeth Y Karlan
Women s Cancer Research Institute, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, California 90048, USA
Obstet Gynecol 110:155-67. 2007..Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress... - Impact of statin therapy on survival in epithelial ovarian cancerR Geoffrey Elmore
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Gynecol Oncol 111:102-5. 2008..We sought to determine the association between use of statins and epithelial ovarian cancer survival, disease progression, and clinico-pathologic factors... - BRCA1 promoter methylation predicts adverse ovarian cancer prognosisJing Wang Chiang
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, 160W, Los Angeles, CA 90048, USA
Gynecol Oncol 101:403-10. 2006..3 months; P = 0.02). CONCLUSION: These data suggest that methylation of the BRCA1 promoter is associated with poor patient outcome. BRCA1 may be part of a global panel of methylated genes associated with aggressive disease... - Ovarian preservation in stage I low-grade endometrial stromal sarcomasAndrew J Li
Department of Obstetrics Gynecology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Obstet Gynecol 106:1304-8. 2005..To examine the impact of ovarian preservation in a case-control study of women with stage I low-grade endometrial stromal sarcomas... - Functional domains of CCN1 (Cyr61) regulate breast cancer progressionJames O'Kelly
Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
Int J Oncol 33:59-67. 2008.... - Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancersAndrew J Li
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Gynecol Oncol 116:78-81. 2010..We have hypothesized that statins influence ovarian cancer outcome through alteration of lipoprotein profiles, and sought to determine correlations between lipoprotein levels and survival in women with advanced stage disease... - Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer riskChristine S Walsh
Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA 90048, USA
Gynecol Oncol 104:660-4. 2007..The objective of this study was to examine the association between SNP309 and sporadic endometrial cancer risk... - Ovarian cancer: the duplicity of CA125 measurementAmer K Karam
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Nat Rev Clin Oncol 7:335-9. 2010.... - Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancerAllison E Axtell
University of California Los Angeles UCLA Medical Center, Los Angeles, CA, USA
J Clin Oncol 25:384-9. 2007..Reciprocally cross validate the predictors identified with those from two previously published cohorts from institutions B and C... - Surgical advances in the treatment of ovarian cancerAndrew J Li
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Hematol Oncol Clin North Am 17:945-56. 2003..Although laparoscopy may be feasible in staging women with disease apparently limited to an ovary, further studies are necessary before it can be considered routinely as an alternative to standard laparotomy... - Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signalingRae Lynn Baldwin
Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Cancer Res 63:1413-9. 2003..These data suggest that TGF-beta/Smad signaling is blocked downstream of Smad complex formation or that an alternate signaling pathway other than TGF-beta/Smad may transmit TGF-beta-induced cell cycle arrest in the ovarian epithelium... - Molecular signatures of ovarian cancer: from detection to prognosisChristine S Walsh
Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Mol Diagn Ther 14:13-22. 2010..In this review, we discuss the current state of biomarker development for the early detection of ovarian cancer and explore the continuing challenges to realizing this goal... - Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignanciesJohn C Elkas
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Walter Reed Army Medical Center, Room 6762, Building 2, 6900 Georgia Avenue NW, Washington, D C 20307, USA
Gynecol Oncol 97:685-92. 2005..As an alternative, a more limited resection with urinary tract reconstruction using ileum for interposition or augmentation may allow for the preservation of urethral voiding... - Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literatureAlexander Liede
Women s Cancer Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 290W, Los Angeles, CA 90048, USA
J Clin Oncol 22:735-42. 2004.... - The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancerChristine H Holschneider
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1740, USA
Clin Cancer Res 11:5756-63. 2005.... - Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motilityLindsay Gillan
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Cancer Res 62:5358-64. 2002..We propose PN functions as a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins to support adhesion and migration of ovarian epithelial cells... - A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
Cancer Gene Ther 9:553-66. 2002..p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53... - Chemotherapy in epithelial ovarian cancerJing Wang
Division of Gynecologic Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, 160W, Los Angeles, CA 90048, USA
Curr Womens Health Rep 2:20-6. 2002..Investigations into novel chemotherapeutic agents and other biologic molecules have led to advances in the therapeutic armamentarium and have improved survival for women with ovarian cancer... - Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cellsM Jane Arboleda
Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
Cancer Res 63:196-206. 2003..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo... - Gene expression in epithelial ovarian carcinomaDaniela Matei
Department of Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, California, CA 90095, USA
Oncogene 21:6289-98. 2002..Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner... - Impact of beta blockers on epithelial ovarian cancer survivalElena S Diaz
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Gynecol Oncol 127:375-8. 2012..We sought to determine the association between beta blocker use and epithelial ovarian cancer (EOC) disease progression and survival... - A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopauseJeannette M Painovich
Department of Medicine, Cedars Sinai Heart Institute, Los Angeles, CA 90048, USA
Menopause 19:54-61. 2012.... - Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancerJennifer A Byrne
Molecular Oncology Laboratory, Oncology Research Unit, The University of Sydney Discipline of Paediatrics and Child Health, The Children s Hospital at Westmead, New South Wales, Australia
Int J Cancer 117:1049-54. 2005..TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number... - Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersWataru Sakai
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Nature 451:1116-20. 2008..Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy... - The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?Beth Y Karlan
J Clin Oncol 25:1303-4. 2007 - Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancerAntonio Santillan
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N Wolfe Street, Phipps 281, Baltimore, MD 21287 1281, USA
Gynecol Oncol 104:686-90. 2007..To evaluate the feasibility and associated survival outcome of secondary cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer... - ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromesJose G Guillem
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:4642-60. 2006.... - ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromesJose G Guillem
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, New York 10021, USA
Ann Surg Oncol 13:1296-321. 2006..Clinical interventions have been formulated for mutation carriers within affected families. The primary interventions for mutation carriers of highly penetrant syndromes are surgical... - Cancer incidence in a population of Jewish women at risk of ovarian cancerAlexander Liede
Centre for Research in Women's Health, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
J Clin Oncol 20:1570-7. 2002..Intensive surveillance by use of CA-125 and ultrasound does not seem to be an effective means of diagnosing early-stage ovarian cancer in this high-risk cohort... - Ovarian cancer screeningNicole Urban
Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP 900, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
Hematol Oncol Clin North Am 17:989-1005, ix. 2003..Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods... - Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxisBeth Y Karlan
Gynecol Oncol 92:519-20. 2004 - Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
J Clin Oncol 24:4324-32. 2006..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted... - Prognostic DNA methylation biomarkers in ovarian cancerSusan H Wei
Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
Clin Cancer Res 12:2788-94. 2006..Such ovarian cancer biomarkers represent a promising approach for the assessment and management of this devastating disease... - Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of RepresentativesBeth Y Karlan
Gynecol Oncol 99:257-60. 2005 - Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositionsJohnathan M Lancaster
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Gynecol Oncol 107:159-62. 2007..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome... - The colon is a pelvic organ too: taking the Couric challengeBeth Y Karlan
Obstet Gynecol 104:907-9. 2004 - Can lifestyle influence genetics?Beth Y Karlan
Nat Clin Pract Oncol 4:555. 2007 - Improving efficiencies in translational scienceBeth Y Karlan
Gynecol Oncol 108:461. 2008